James George is a Gastroenterology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1751 York Ave
New York, NY 101286828
Telephone
212-369-2490Registry record last updated 24 May 2016.
Clinical trials
- Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Sponsor: Insel Gruppe AG, University Hospital Bern
- Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Sponsor: Carelon Research
- Red Cell Storage Duration Study
Sponsor: Carelon Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year2025130 payments$105,199openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year2025122 payments$31,156openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year202552 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.5%Proton pump inhibitor26.8%Pantoprazole Sodium54%Omeprazole31%Dexlansoprazole Dr15%Part D<11 patientsAntidiarrheal14.1%Diphenoxylate-Atropine100%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
22.7%Interleukin-12 Antagonist19.7%Stelara100%Part D≥12 patientsTNF inhibitor3%Humira(Cf) Pen100%Part D<11 patientsAnti-infectives
4.3%Penicillins with extended spectrum4.3%Amoxicillin-Clavulanate Potass100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”